Top

European Journal of Nuclear Medicine and Molecular Imaging

Published in:

01-07-2016 | Editorial Commentary

Can ⁶⁸GA-PSMA or radiolabeled choline PET/CT guide salvage lymph node dissection in recurrent prostate cancer?

Authors: Fabio Zattoni, Andrea Guttilla, Laura Evangelista

Published in: European Journal of Nuclear Medicine and Molecular Imaging | Issue 8/2016

Excerpt

In this issue of the European Journal of Nuclear Medicine and Molecular Imaging, Pfister et al. [1] evaluate the performance of ¹⁸F-fluoroethylcholine (¹⁸F-FEC) and ⁶⁸Ga-PSMA PET/CT in patients undergoing salvage lymph node dissection (sLND) for recurrent prostate cancer (PCa). The introduction of novel imaging modalities and tracers has increased the detection of oligometastatic PCa recurrence, potentially justifying the use of sLND rather than a systemic approach. The present study is premised on the notion that radiopharmaceutical agents can be useful for guiding surgical procedures in cases of predominant nodal recurrence of PCa. This is a topic of great interest to urologists, radiologists and nuclear medicine physicians. What evidence must we consider for the use of sLND? Could extended LND rather than sLND during radical prostatectomy (RP) improve patient survival? What is the best imaging modality for ensuring appropriate treatment? …

Pfister D, Porres D, Heidenreich A, Heidegger I, Knuechel R, Steib F, et al. Detection of recurrent prostate cancer lesions before salvage lymphadenectomy is more accurate with Ga-PSMA-HBED-CC than with F-fluoroethylcholine PET/CT. Eur J Nucl Med Mol Imaging. 2016. doi:10.1007/s00259-016-3366-9. In press.

Epstein JI, Egevad L, Amin MB, Dalahunt B, Srigley JR, Humphrey PA, et al. The 2014 International Society of Urological Pathology (ISUP) consensus conference on Gleason grading of prostatic carcinoma: definition of grading patterns and proposal for a new grading system. Am J Surg Pathol. 2016;40:244–52.PubMed

Abdollah F, Briganti A, Montorsi F, Stenzl A, Stief C, Tombal B, et al. Contemporary role of salvage lymphadenectomy in patients with recurrence following radical prostatectomy. Eur Urol. 2015;67:839–49.CrossRefPubMed

Zattoni F, Nehra A, Murphy CR, Rangel L, Mynderse L, Lowe V, et al. Mid-term outcomes following salvage lymph node dissection for prostate cancer nodal recurrence status post–radical prostatectomy. Eur Urol Focus. 2016. doi:10.1016/j.euf.2016.01.008. In press.

Ost P, Bossi A, Decaestecker K, De Meerleer G, Giannarini G, et al. Metastasis-directed therapy of regional and distant recurrences after curative treatment of prostate cancer: a systematic review of the literature. Eur Urol. 2015;67:852–63.CrossRefPubMed

Rigatti P, Suardi N, Briganti A, Da Pozzo LF, Tutolo M, Villa L, et al. Pelvic/retroperitoneal salvage lymph node dissection for patients treated with radical prostatectomy with biochemical recurrence and nodal recurrence detected by [11C]choline positron emission tomography/computed tomography. Eur Urol. 2011;60:935–43.CrossRefPubMed

Suardi N, Gandaglia G, Gallina A, Di Trapani E, Scattoni V, Vizziello D, et al. Long-term outcomes of salvage lymph node dissection for clinically recurrent prostate cancer: results of a single-institution series with a minimum follow-up of 5 years. Eur Urol. 2015;67:299–309.CrossRefPubMed

Rinnab L, Mottaghy FM, Simon J, Volkmer BG, de Petriconi R, Hautmann RE, et al. [11 C] Choline PET/CT for targeted salvage lymph node dissection in patients with biochemical recurrence after primary curative therapy for prostate cancer. Urol Inter. 2008;81:191–7.CrossRef

Title: Can 68GA-PSMA or radiolabeled choline PET/CT guide salvage lymph node dissection in recurrent prostate cancer?
Authors: Fabio Zattoni
Andrea Guttilla
Laura Evangelista
Publication date: 01-07-2016
Publisher: Springer Berlin Heidelberg
Published in: European Journal of Nuclear Medicine and Molecular Imaging / Issue 8/2016
Print ISSN: 1619-7070
Electronic ISSN: 1619-7089
DOI: https://doi.org/10.1007/s00259-016-3401-x

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Can ⁶⁸GA-PSMA or radiolabeled choline PET/CT guide salvage lymph node dissection in recurrent prostate cancer?

Excerpt

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Excerpt

Please log in to get access to this content

Other articles of this Issue 8/2016

Development of a nomogram combining clinical staging with 18F-FDG PET/CT image features in non-small-cell lung cancer stage I–III

The reproducibility and prognostic value of serial measurements of heart rate response to regadenoson during myocardial perfusion imaging

Intra-individual comparison of 68Ga-PSMA-11-PET/CT and multi-parametric MR for imaging of primary prostate cancer

The 2015 Revised American Thyroid Association guidelines for the management of medullary thyroid carcinoma: the “evidence-based” refusal to endorse them by EANM due to the “not evidence-based” marginalization of the role of Nuclear Medicine

Diagnostic imaging to detect and evaluate response to therapy in bone metastases from prostate cancer: current modalities and new horizons

Clinical use of quantitative cardiac perfusion PET: rationale, modalities and possible indications. Position paper of the Cardiovascular Committee of the European Association of Nuclear Medicine (EANM)